Articles from Peptilogics

Tim Czartoski, orthopedic executive and former president of DePuy Synthes U.S. and most recently president of U.S. Surgical and Global R&D at Enovis, has joined the Peptilogics board of directors. His background in leading large orthopedic device businesses, including successful launches of robotic technology platforms and one of the industry’s most advanced knee systems, lends significant value to Peptilogics as it moves towards bringing meaningful innovation to market. Czartoski sees tremendous opportunity in therapeutic solutions that advance or complement current approaches to prosthetic joint infections (PJI) and medical device-related infections (MDRI), complications that have been addressed almost exclusively through device and surgical innovation for more than fifty years.

Peptilogics, a surgical therapeutics company dedicated to curing and preventing devastating medical device-related infections (MDRI), has announced the enrollment of the first patient in the RETAIN Phase 2/3 registration trial by Dr. Toan Le at the University of Cincinnati Medical Center. The trial is evaluating PLG0206, a first-in-class anti-biofilm drug candidate, in patients with prosthetic joint infection (PJI), the first of multiple potential MDRI indications. PJI represents the largest unmet need in orthopedics and a significant entry point into a broader MDRI market that affects millions of patients annually.

Peptilogics, a clinical-stage biotechnology company, today announced new top-line interim data for PLG0206 in periprosthetic joint infection (PJI) patients from their ongoing Phase 1b trial. At 180-days following treatment with PLG0206 administered during a DAIR (Debridement, Antibiotics, and Implant Retention) surgery, no treatment-related serious adverse events were reported in either cohort. One recurrence was observed in the trial (one of 14 patients, 7%), which was in the Low Dose cohort at Day-180; no recurrences were observed in the High-Dose cohort. This is significantly lower (p=0.029) than the 55% 180-day recurrence rate observed in a similar patient population reported by Zhu, et.al in the Journal of Arthroplasty in 2021. Detailed analyses will be presented at various conferences in the coming months.

Peptilogics, a clinical-stage biotechnology company, today announced top-line interim data of PLG0206 in PJI patients from their ongoing Phase 1b trial. At 90 days post-Debridement, Antibiotics, and Implant Retention (DAIR) surgery, there were no treatment-related adverse events reported in the low-dose cohort. Additionally, zero infection recurrences were observed in this subset of patients compared to 44% recurrence rate in historical controls as shown by Zhu, et.al in the Journal of Arthroplasty in 2021 at 90 days. Detailed analyses along with data from the high-dose cohort will be presented at conferences in the coming months.

Peptilogics, a clinical stage biotechnology company, has completed the enrollment of a Phase 1b trial for PLG0206 in patients undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for treatment of a Periprosthetic Joint Infection (PJI) occurring after Total Knee Arthroplasty (TKA). The trial is an open-label dose-escalating study with two dose cohorts of seven patients each compared to historical controls.

Peptilogics, a clinical stage biotech company engineering peptide therapeutic solutions for patients with life-threatening diseases, today announced that it will host a virtual panel discussion with leading industry experts on the high unmet medical need, economic burden, and opportunity in periprosthetic joint infections (PJI) on Monday, February 27, 2023 at 11 AM ET.

Peptilogics, a clinical stage biotech company engineering peptide therapeutic solutions for patients with life-threatening diseases, is presenting two posters featuring preclinical data from its antimicrobial peptide, PLG0206, at IDWeek 2022. The studies demonstrate the potent activity of PLG0206 against bacteria that cause periprosthetic joint infections (PJI), including multidrug resistant (MDR) bacteria. PJI is the most common complication of joint replacement surgery and is a life-changing event for patients. PJI treatment currently requires an average of three major surgeries per patient, which adds a significant burden on patients, surgeons and the healthcare system. With up to a 60% failure rate and a five-year mortality of 25%, this debilitating condition surpasses the death rates of many cancers. In addition, the increased post-surgical use of standard antibiotics can lead to MDR, a major growing public health concern with few or no therapeutic solutions. MDR related infections pose a significant concern to patients as well as society in both the short- and long-term. These challenges necessitate finding new solutions for treating PJI, including those caused by MDR bacteria.

Peptilogics, a clinical stage biotech company engineering peptide therapeutic solutions for patients with life-threatening diseases, presented preclinical data from its peptide, PLG0206, at the ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance. Data presented demonstrate activity of PLG0206 against multi-drug resistant pathogens and suggest that this novel antimicrobial peptide could potentially address difficult to treat bacterial infections.

Peptilogics, a clinical stage biotech company engineering peptide therapeutic solutions for patients with life-threatening diseases, today announced it has dosed its first patient with PLG0206 in the LOGIC-1 trial for the treatment of periprosthetic joint infections (PJI) occurring after a total knee arthroplasty (TKA). PLG0206 was designed with a unique mechanism of action intended to directly address persistent bacterial pathogens within the biofilm that evade standard of care antibiotics. PLG0206, an investigational product, has been granted FDA Orphan Drug, Fast Track and Qualified Infectious Disease Product (QIDP) Designations for the treatment of PJI.

EpiAxis Therapeutics, a leading epigenetics company with a focus on the treatment, diagnosis and monitoring of cancer and the prevention of its recurrence, and Peptilogics, a biotech company engineering peptide therapeutics by combining computation and biology to improve the treatment landscape for patients with life-threatening diseases, announced today that they have entered a collaboration to leverage AI for drug discovery to inhibit epigenetic oncology targets, aiming to reprogram cancer cells and drive immune reinvigoration.

Peptilogics, a clinical stage biotech company engineering peptide therapeutic solutions for patients with life-threatening diseases, today announced two executive appointments to strengthen and expand its leadership team. Atul Deshpande, Ph.D., MBA, A-PMP, has been appointed to Chief Strategy Officer and Nicholas Pachuda, DPM, has been promoted to Chief Operating Officer.

Peptilogics, a biotech company engineering peptide therapeutics to improve the treatment landscape for patients with life-threatening diseases, will participate in the Musculoskeletal Infection Society (MSIS) 32nd Annual Open Scientific Meeting taking place in Pittsburgh August 5-6. This pinnacle event will feature a multidisciplinary scientific forum for the advancement of knowledge in the field of musculoskeletal infection and contribute to the education of clinicians and researchers to guide patient care.

Peptilogics, a biotech company engineering peptide therapeutics to improve the treatment landscape for patients with life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s lead drug candidate, PLG0206, for the treatment of periprosthetic joint infection (PJI).

Orion Biotechnology Canada Ltd, a drug discovery company targeting previously undruggable G Protein-Coupled Receptors (GPCRs), and Peptilogics, a biotech company engineering peptide therapeutics by combining computation and biology to improve the treatment landscape for patients with life-threatening diseases, announced today that they have entered a research and development collaboration to leverage AI for drug discovery against an undrugged GPCR target.

Peptilogics, a biotech company engineering peptide therapeutics to improve the treatment landscape for patients with life-threatening diseases, will present one poster and an oral presentation at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). The preclinical data highlight the potent antimicrobial properties of Peptilogics’ designed peptide PLG0206 for the treatment of periprosthetic joint infection (PJI), a rare and life-threatening complication that patients may develop following joint replacement surgery. PLG0206, an investigational product, is currently being evaluated in an ongoing Phase 1b clinical study (Study in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Occurring After Total Knee Arthroplasty (TKA)).

Peptilogics, a biotech company engineering peptide therapeutics to improve the treatment landscape for patients with life-threatening diseases, will present three papers at the American Academy of Orthopedic Surgeons (AAOS) 2022 Annual Meeting in Chicago March 24. The paper presentations highlight the potent antimicrobial activity of Peptilogics’ lead investigational engineered peptide PLG0206. The preclinical data showed that PLG0206 reduced biofilm mass and increased survival of animals infected with multi-drug resistant ESKAPE pathogens for the treatment of periprosthetic joint infection (PJI). A Phase 1b clinical study of PLG0206 for the treatment of PJI is ongoing.

Peptilogics, a biotech company that designs peptide therapeutics, today announced that it has promoted Nicholas Nystrom, Ph.D., formerly SVP and Head of Computation and Data, to Chief Technology Officer. In this role, Dr. Nystrom will lead technology strategy, as well as the implementation and advancement of Peptilogics’ computational peptide design platform that unites novel artificial intelligence technology and supercomputing with biological and pharmaceutical expertise to optimize peptide therapeutics.

Peptilogics, a biotech company that engineers peptide therapeutics to radically improve the treatment landscape for patients with life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Investigational New Drug Application (IND) for PLG0206 to treat periprosthetic joint infection (PJI) allowing the Phase 1b study to proceed.

Peptilogics, a biotech company that engineers peptide therapeutics to improve the treatment landscape for patients with life-threatening diseases, today announced that the company received an award from the Cystic Fibrosis Foundation. The award will support preclinical research in a new class of engineered antibacterial peptides intended to serve as the first line of defense against invading pathogens, particularly bacteria, including multidrug resistant isolates that live in the airways of the lungs of cystic fibrosis (CF) patients and resist common antibiotic treatments.

Peptilogics, a biotech company that designs peptide therapeutics to radically improve the treatment landscape for patients with serious and life-threatening diseases, today announced two studies on its lead designed peptide therapeutic, PLG0206, an investigational drug, have been published in peer-reviewed journals Antimicrobial Agents and Chemotherapy (AAC) and Microbiology Spectrum.

Peptilogics, a biotech company that engineers peptide therapeutics to radically improve the treatment landscape for patients with life threatening diseases, today presented Phase 1 safety and tolerability data on PLG0206, a unique engineered antibacterial peptide being developed for the treatment of prosthetic joint infection (PJI). The first-in-human trial showed that PLG0206 intravenously administered was well tolerated in healthy volunteers, with linear PK over the dose range. Data were presented at IDWeek 2021.

Peptilogics, a biotech company that engineers peptide therapeutics to radically improve the treatment landscape for patients with life threatening diseases, will present first-in-human Phase 1 data on its lead investigational therapy PLG0206 for the treatment of prosthetic joint infection (PJI) at IDWeek 2021 taking place September 29 through October 3.